Contrasting Vivos Therapeutics (NASDAQ:VVOS) & Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical (NASDAQ:DRTS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Earnings and Valuation

This table compares Alpha Tau Medical and Vivos Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.45)	-5.69
Vivos Therapeutics	$14.58 million	1.26	-$13.58 million	($5.68)	-0.55

Vivos Therapeutics has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Alpha Tau Medical has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, indicating that its stock price is 647% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alpha Tau Medical and Vivos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	2	0	3.00
Vivos Therapeutics	0	0	2	0	3.00

Alpha Tau Medical presently has a consensus target price of $8.00, indicating a potential upside of 212.50%. Vivos Therapeutics has a consensus target price of $6.30, indicating a potential upside of 102.57%. Given Alpha Tau Medical’s higher probable upside, analysts plainly believe Alpha Tau Medical is more favorable than Vivos Therapeutics.

Profitability

This table compares Alpha Tau Medical and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-38.62%	-29.89%
Vivos Therapeutics	-86.19%	-335.04%	-93.58%

Summary

Alpha Tau Medical beats Vivos Therapeutics on 6 of the 11 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.